respective Kaplan-Meier estimates for OS and PFS rates at 6 months were 70% and 31%. The respective median OS and PFS were not-reached and 94 days. The respective RR at weeks 7, 13, and 25 were 24%, 12% and 11%. No death related to treatment was observed. Although 9 patients experienced >grade 3 toxicity (7, neutropenia; 2, anemia; 1, retroperitoneal abscess), they all recovered. Conclusions: ERB is a well-tolerated regimen with promising activity in TAX-resistant CAS. The common toxicity is neutropenia, which requires growth factor support. This study is underway and enrollment is expected to be completed in 2018. This study may provide a new treatment option for patients with PTX-resistant CAS. Hematology Oncology, Mayo Clinic, Rochester, NY, USA Background: Angiosarcoma has a particularly poor prognosis with 5 year overall survival rates of approximately 30-40%. Treatment of locally advanced and metastatic angiosarcoma is inadequate. Data strongly suggest concurrent, potent inhibition of VEGFR and Tie2 represents an attractive therapeutic strategy in angiosarcoma. Regorafenib displays potent VEGFR and Tie2 receptor inhibition and also possesses activity against additional potential targets in angiosarcoma including PDGFRs, RAF, KIT and FGFR. Methods: A multicenter phase II study of regorafenib in patients with locally advanced or metastatic angiosarcoma was conducted through the Midwest Sarcoma Trials Partnership. Adequate performance status, organ function, measurable disease (RECIST 1.1) and 1-4 prior therapies were required. Regorafenib 160 mg PO daily was given in 28 day cylces (21 days on, 7 days off) until disease progression (PD) or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), assessed at 16 weeks. Secondary endpoints include overall response rate (ORR), clinical benefit rate (CBR), OS, and safety and tolerability. A Simon 2-stage design was used. Results: A total of 18 pts were enrolled at 5 sites, 14 are evaluable for response. Median age was 55.6 (range 21-82); 61% were female; 72% metastatic disease. PFS at 4 months is 46% with a median PFS and OS of 2.7 and 15 months, median follow-up 7.9 months (0.4-23). 1 confirmed CR and PR, 5 SD and 7 PD were observed. ORR and CBR are 14 and 50%, respectively. Common grade 3-4 adverse events were as expected. Conclusions: Regorafenib was well tolerated in this study of pretreated patients with angiosarcomas. Median PFS and PFS at 4 months are promising. Regorafenib will continue to be explored in this two-stage optimal Simon design, for a total of 31 patients. Clinical trial identification: NCT02048722. Legal entity responsible for the study: Northwestern University. Funding: Bayer HealthCare. Disclosure: All authors have declared no conflicts of interest. Radiotherapy, Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, Romania, 2 Surgery, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, 3 Biostatistics, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, Cluj-Napoca, Romania, 4 Pathology, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, ClujNapoca, Romania, 5 Epidemiology, The Oncology Institute "Prof.Dr.Ion Chiricuta" ClujNapoca, Cluj-Napoca, Romania
Background: Angiosarcoma has a particularly poor prognosis with 5 year overall survival rates of approximately 30-40%. Treatment of locally advanced and metastatic angiosarcoma is inadequate. Data strongly suggest concurrent, potent inhibition of VEGFR and Tie2 represents an attractive therapeutic strategy in angiosarcoma. Regorafenib displays potent VEGFR and Tie2 receptor inhibition and also possesses activity against additional potential targets in angiosarcoma including PDGFRs, RAF, KIT and FGFR. Methods: A multicenter phase II study of regorafenib in patients with locally advanced or metastatic angiosarcoma was conducted through the Midwest Sarcoma Trials Partnership. Adequate performance status, organ function, measurable disease (RECIST 1.1) and 1-4 prior therapies were required. Regorafenib 160 mg PO daily was given in 28 day cylces (21 days on, 7 days off) until disease progression (PD) or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), assessed at 16 weeks. Secondary endpoints include overall response rate (ORR), clinical benefit rate (CBR), OS, and safety and tolerability. A Simon 2-stage design was used. Results: A total of 18 pts were enrolled at 5 sites, 14 are evaluable for response. Median age was 55.6 (range 21-82); 61% were female; 72% metastatic disease. PFS at 4 months is 46% with a median PFS and OS of 2.7 and 15 months, median follow-up 7.9 months (0.4-23). 1 confirmed CR and PR, 5 SD and 7 PD were observed. ORR and CBR are 14 and 50%, respectively. Common grade 3-4 adverse events were as expected. Conclusions: Regorafenib was well tolerated in this study of pretreated patients with angiosarcomas. Median PFS and PFS at 4 months are promising. Regorafenib will continue to be explored in this two-stage optimal Simon design, for a total of 31 patients. Clinical trial identification: NCT02048722. Legal entity responsible for the study: Northwestern University. Funding: Bayer HealthCare. Disclosure: All authors have declared no conflicts of interest. Radiotherapy, Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, Romania, 2 Surgery, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, 3 Biostatistics, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, Cluj-Napoca, Romania, 4 Pathology, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, ClujNapoca, Romania, 5 Epidemiology, The Oncology Institute "Prof.Dr.Ion Chiricuta" ClujNapoca, Cluj-Napoca, Romania
Background: Angiosarcoma is a rare malignancy, and the data about its clinicopathological features and prognostic factors are limited. The purpose of this study was to present a retrospective analysis of angiosarcoma patients treated at a single institution. Methods: Clinical and pathological features of 41 patients treated in our institution between 1998 and 2016 were analyzed. Results: Of the 41 patients included, 53.7% were women and 46,3% were men and median age was 60 (16-81). 34.1% cases were located in the soft tissues (ST) of the limbs or trunk, 24.4% in the viscera (V), 19.5% in the breast (B), 14.6% involved the head and neck (HN) and 7.3% in the bone (B). The overall survival (OS) at 5 years was 26% (IC: 15% -42%), with a median survival of 14.9 months. For the 17.1% patients that were alive at the time of analysis, the median follow up was 60 months (16.1-222.1).The tumor sites for the 7 surivors involved B(4), ST(1), HN(1) and V(1). Radiation induced angiosarcoma was suspected in 17.1% patients. Chronic lymphedema was described/ highly probable for 19.5% of the patients. Surgery(S) was performed in 82.9% cases, chemotherapy(CT) in 41.5% cases, and radiation therapy(RT) for 9.8% of cases. CT was more likely to be given to younger patients, but did not improve OS. The pathology report was uncertain for 39% cases at first examination. Superficial tumors (B, ST and HN) had a better OS than deep tumors (V,B) but not statistically significant (31%vs15%). Women had a significant better OS compared to men (36%vs16%, p ¼ 0.02). OS at 5 years for patients under age 67 was 30%, and 17% for patients above 67 (p ¼ 0.07). Tumor grade was assesed for 85.4% cases. Grade 1(G1) was found in 12.2%, G2 in 36.6% and G3 in 36.6% patients. Patients having G3 tumors had a lower OS, but not statistically significant. Relapse occured at 58.5% of the patients (from 1 to 4 episodes). Of all relapses, 68.3% occured locally, 7.3% regionally, and 48.8% were distant metastases. The most common metastatic sites were lung (7 cases), bone (4), skin (4) and liver (3). Conclusions: Angiosarcoma is an agressive tumor that was often underrecognized, occuring in various sites. Women with history of radiotherapy or lymphedema are at higher risk, but have a better prognosis. Younger patients and lower grade seem to have a longer survival. Legal entity responsible for the study: Chirila Monica-Emilia. Background: Retroperitoneal soft tissue sarcomas (RPS) are rare tumors. Despite surgery, 5% to 36% of patients experience locoregional recurrence (LR) the optimum treatment of which is still debated. The aim the study of to report our experience in treating LR. Methods: All 297 consecutive patients operated for a non-metastatic primary RPS between 1994 and 2017 were retrospectively analyzed to identify patients who developed LR. Demographic data, treatment variables and long-term outcome were recorded to calculate disease free survival (DFS), overall survival (OS) and predictive factors of recurrence. Results: After a median follow-up of 97 months, 55 patients (19%) developed LR. The first site of recurrence was locoregional in 100% with associated peritoneal metastases in 45% and distant metastases in 5%. The median disease free interval (DFI) was 24 months. After recurrence treatment, the 1-, 3-and 5-year OS rates were 71%, 46% and 33%, and 1-, 3-and 5-year DFS rates were 50%, 22%, and 15%. Low tumor grade, DFI above 24 months, exclusive LR and well-differentiated liposarcoma were predictive of better OS and DFS. Despite finding no statistical difference between treatment strategies, median OS was less than 1 month after best supportive care, 44 months after chemotherapy (including patients who underwent subsequent LR radiotherapy or surgery) and was not reached after upfront surgery or radiotherapy. Fourteen patients underwent initial surveillance for low-grade liposarcoma and eventually required treatment in 86% after a median delay of 20 months during which no patient developed distant metastases.
Conclusions: The management of LR in RPS is complex. An initial surveillance may not alter survival in asymptomatic low-grade and slow-growing LR. A LR decision scheme is proposed. Legal entity responsible for the study: Gustave Roussy. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. 
